Ionis gets into gene editing
The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.
PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Ovid takes a novel approach to gene therapy
Ovid and its partner Gensaic have high hopes for a brand-new delivery method, and much to prove.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
